Depression Progress Note: SOAP Examples for MDD Follow-Up

Why MDD Follow-Up Notes Matter

Every depression progress note serves three jobs at once. First, it is a clinical handoff: the next psychiatrist, therapist, or covering provider needs to know severity, trajectory, and what was tried. Second, it is a medical necessity record: insurers expect evidence that continued care is still required and that medication changes are reasoned. Third, it is a risk document: suicidal ideation screening, including PHQ-9 item #9, must appear every visit — a documented negative is protective; silence is a gap.

• Show symptom course since the last visit with concrete functional impact.
• Record PHQ-9 total and item #9 every visit, with trend from prior scores.
• State response stage: no response, partial response, full response, or remission.
• Justify every start, stop, titration, switch, or augmentation with a clinical rationale.
• Formulate suicide risk with risk factors, protective factors, and the safety plan.
• Connect the Plan to the Assessment so medical necessity for continued care is explicit.

If the note could belong to any depressed patient on any day, it is not doing its job. MDD follow-up documentation should let a reviewer reconstruct why this dose, this interval, and this level of monitoring make sense today.

Think of the depression progress note as a serial story with measured chapters. Intake establishes the episode; each follow-up must show what changed, what did not, and what you are doing about the gap. That serial structure is what separates a defensible chart from a stack of interchangeable 'continue current plan' entries.

Partial Response vs Full Response vs Remission

Response language is not optional flavor text — it drives the Plan. Using 'improved' for every visit hides whether you should titrate, switch, augment, or space follow-ups. Anchor Assessment language to standard clinical definitions and to your scale scores.

Be precise about residual symptoms. 'Partial response' should name what remains — sleep, anhedonia, concentration, guilt, SI — so the next visit has a target. 'In remission' should not appear if PHQ-9 is still in the moderate range or if the patient reports persistent functional impairment.

PHQ-9 Trajectory and Item #9 Every Visit

Standardized scales turn a narrative into a measurable course of illness. For MDD follow-up, the PHQ-9 is the most common tool: record the total score, compare it to the prior visit(s), and briefly interpret the direction. A single number without context is weak; a trajectory with functional correlates is strong.

Document item #9 (thoughts that you would be better off dead, or of hurting yourself) at every visit — even when the total PHQ-9 is low and even when the patient denies SI in conversation. Treat a score of 0 as a documented negative finding. If item #9 is ≥1, expand the risk assessment: passive vs active ideation, plan, intent, means, and protective factors. Do not bury a positive item #9 in 'PHQ-9 = 14' without comment.

• Record: 'PHQ-9 today 11 (prior visit 16; intake 21). Item #9 = 0.'
• Note which symptom domains improved most (sleep, energy, mood) and which lagged.
• If scores and narrative conflict (low PHQ-9 but high functional disability), document both and reconcile in Assessment.
• For acute risk changes, do not rely on the scale alone — expand clinical SI/HI screening in Subjective and Assessment.

Over a treatment course, a short score trail in each note ('21 → 16 → 12 → 7') is one of the clearest medical necessity signals you can leave. It also supports decisions about when to consider next-step treatments, including neuromodulation for TRD — see our TMS clinical documentation guide when the chart is building toward that threshold.

Documenting SSRI Titration and Augmentation

Every medication change needs a why. 'Increase sertraline to 150 mg' without rationale fails audit review and leaves the next clinician guessing. Pair the action with the response stage, tolerability, adherence, and duration of the current trial.

What belongs in the Plan for a dose change

• Current medication, dose, duration at that dose, and adherence.
• Response stage and key residual symptoms or side effects.
• Specific change (titrate, switch, augment, discontinue) with target dose and titration schedule.
• Risks discussed (activation, sexual side effects, serotonin syndrome, discontinuation symptoms) and patient agreement.
• Monitoring plan: follow-up interval, labs if relevant, and what will trigger the next change.

Example rationale language

Titration: 'Increasing escitalopram from 10 mg to 15 mg daily for partial response after 4 weeks at 10 mg (PHQ-9 18 → 13) with good tolerability; residual anhedonia and middle insomnia. Discussed possible side effects; patient agreeable.'

Augmentation: 'Adding aripiprazole 2 mg qAM to sertraline 150 mg for treatment-resistant MDD after two adequate antidepressant trials with only partial response (current PHQ-9 14). Reviewed metabolic and akathisia risks; baseline weight and AIMS documented; labs ordered.'

When documenting TRD, list failed adequate trials by agent, dose, duration, and reason for discontinuation (inefficacy vs intolerance). That history is what payers and TMS programs look for. Link incomplete response after multiple trials to next-step options and document the conversation — including referral for TMS when clinically appropriate.

Depression Progress Note SOAP Template

Use this as a fillable skeleton for outpatient MDD med-management or therapy-informed follow-up. Trim what does not apply; do not skip risk or PHQ-9.

Depression Progress Note Examples

Four complete MDD follow-up examples. Names and details are illustrative. Notice how response language, PHQ-9 trajectory, item #9, and medication rationale appear in every note.

Example 1 — Partial Response with SSRI Titration

Elena is a 34-year-old returning 4 weeks after starting sertraline for a moderate MDD episode. Symptoms improved but remain clinically significant — classic partial response documentation.

Example 2 — Remission Maintenance

Marcus is stable in remission on maintenance SSRI. The note must still document PHQ-9, item #9, and why continued treatment (not discharge) is appropriate.

Example 3 — Treatment-Resistant Depression / Augmentation

Priya has failed two adequate antidepressant trials. The note documents TRD, lists prior trials, justifies augmentation, and opens the door to neuromodulation if needed.

Example 4 — Therapy-Focused MDD Session

Jordan is in weekly CBT with coordinated med management elsewhere. This example shows a therapy-forward depression progress note that still carries medical necessity, scales, and risk — useful when psychotherapy is the primary service billed that day.

Medical Necessity for Continued MDD Care

Payers do not assume that 'history of depression' justifies indefinite weekly visits or ongoing medication management. Your Assessment and Plan should make necessity explicit whenever intensity, duration, or specialty level of care could be questioned.

• Tie continued care to current severity, residual symptoms, and functional impairment — not only to the original diagnosis.
• Show trajectory: improving but not remitted, remitted but high relapse risk, or TRD requiring next-step treatment.
• Document failed or incomplete response to lower-intensity interventions when escalating care.
• State the treatment goal for the next interval (e.g., PHQ-9 <5, return to full-time work, extinguish passive SI).
• For remission maintenance, cite relapse history or recurrent course as the reason pharmacotherapy continues.

Example sentence you can adapt: 'Continued outpatient psychiatric management is medically necessary given persistent moderately severe MDD (PHQ-9 14) with occupational impairment after an adequate SSRI trial; plan is augmentation with close risk monitoring and reassessment in 2 weeks.'

Spacing visits is also a medical necessity decision. Moving from every 2 weeks to every 3 months should be justified by remission or full response, low risk, and a clear maintenance goal — not by calendar convenience alone. Conversely, keeping a high-acuity patient on a long interval while PHQ-9 remains elevated undercuts both safety and necessity.

Common Depression Progress Note Mistakes

Calling every visit 'improved' or 'stable'

Those words erase the difference between partial response and remission. Name the response stage and residual targets so titration or maintenance decisions are defensible.

PHQ-9 without item #9 or without trend

A lone total score is incomplete. Document item #9 every visit and compare to prior scores. A rising item #9 with a falling total still demands expanded risk assessment.

Medication changes without rationale

'Increase to 100 mg' without linking to partial response, duration at current dose, and tolerability looks arbitrary on review. Write the clinical logic in the Plan.

Skipping SI screening when the patient 'seems fine'

Remission notes still need an explicit negative SI/HI screen. Absence of documentation is not the same as absence of risk inquiry.

TRD claimed without listing adequate trials

If you are documenting treatment resistance or referring for TMS, list agents, doses, durations, and outcomes. Vague 'failed multiple antidepressants' is often insufficient for payer and program review.

Plan that ignores Assessment

If Assessment says partial response with residual insomnia and the Plan only says 'continue current meds, f/u 3 months,' the chart does not support your reasoning. Align interval and interventions with severity.

Let Augustun Draft Your Depression Progress Notes

MDD follow-up visits move quickly: interval history, scales, side effects, risk, and a precise medication decision. Capturing that while staying present is hard. Augustun for psychiatry listens during the encounter and drafts a structured SOAP progress note — including MSE language, PHQ-9 context when discussed, ICD-10 suggestions, and a plan with medication rationale — for you to review and sign.

Augustun supports SOAP, SOAPIE, DAP, and BIRP formats, works for med-management and therapy-informed visits, and connects to 400+ EHRs through a browser extension so finished notes land where you already chart. It is built for clinical use with HIPAA compliance, and recordings are never stored.

Conclusion

A strong depression progress note makes MDD follow-up legible: response stage, PHQ-9 trajectory with item #9, explicit risk formulation, and a medication or therapy plan that answers the Assessment. That is what protects patients, supports medical necessity, and helps the next clinician act without guessing.

Start from the template, adapt one of the four examples to your patient, and keep response language honest. Whether you write the note yourself or use an AI scribe to draft it, clear MDD documentation is clinical care — not afterthought paperwork. For related formats, see our guides on psychiatric SOAP notes, psychiatry notes, and TMS clinical documentation.